MustGrow Biologics Reports $1.4M Licensing Revenue in Q2

Published: 2026-08-31 23:16:56 |

MustGrow Biologics (MGRO:CA) reported $75,000 in TerraSante sales during the second quarter of 2026, but recorded a gross loss of about $17,000. The loss was attributed to expensive air freight from Asia to the United States. The company recognized approximately $1.4 million in licensing revenue. MustGrow said the related cash had been received, although it was recorded as accounts receivable in the Q2 financial statements. Quarterly operating expenses have normalized at about $900,000 following the discontinuation of NexusBioAg. MustGrow reported net profit of roughly $300,000, including discontinued operations. The earnings call was led by President and CEO Corey Giasson and COO Colin Bletsky. Management cautioned that its remarks included forward-looking statements subject to business and financial risks. For traders, the key MustGrow Biologics earnings signals are the licensing income, low TerraSante sales and continued reliance on cost control. The results are more relevant to small-cap biotechnology investors than to the cryptocurrency market.

Neutral

The news is neutral for the cryptocurrency market because MustGrow Biologics is a biotechnology company and the article contains no cryptocurrency, blockchain or digital-asset activity. Its $1.4 million licensing revenue and approximately $300,000 net profit may support sentiment in the small-cap biotechnology sector, but they do not change crypto market fundamentals such as Bitcoin liquidity, stablecoin flows, token demand or regulatory conditions. In the short term, the report could affect MGRO:CA through trading in response to licensing income, TerraSante sales and the company’s gross loss caused by freight costs. However, there is no clear transmission channel to major crypto assets. Similar company-specific earnings announcements have generally had little lasting effect on Bitcoin or broader digital-asset indices unless they involve crypto-related investments, partnerships or regulatory developments. Longer term, continued licensing receipts and lower operating expenses could improve MustGrow’s financial position. Conversely, weak product sales and logistics costs remain risks for the company. Neither factor is likely to materially influence cryptocurrency market stability, so traders should treat the announcement as sector-specific rather than as a crypto trading catalyst.